Delivering an Affordable, Non-Invasive Screening Test for Early Detection of Ovarian and Endometrial Cancers

About

While early cancer detection is the key to survival, many patients are diagnosed after the disease has progressed. A regular affordable screening test for ovarian and endometrial cancers would radically improve survival rates.

Inanna Diagnostics is developing a proprietary technology that enables isolation of a previously untapped source of DNA material for non-invasive early screening applications.

We are a team of seasoned scientists, entrepreneurs and diagnostics experts who have developed new science, built companies and delivered novel diagnostics solutions to the market.

Maya Tevlin, PhD

Founder & CEO

Cancer Genetics and Genomics, The Hebrew University, The Rockefeller University

Ilya Kupershmidt

Cofounder

Serial Enterpreneur, Genomics, Biomedical Informatics. Illumina, NextBio, Karolinska Institute

Katherine Tynan, PhD

Head Diagnostic Strategy

Involved in $1B+ of investments in the precision medicine arena: Geneoscopy, GeneWeave, Life Technologies

Summary of technology

Our early cancer detection technology is based on the unique and patented method for processing pap smear samples.

Regular Pap-test

Process to obtain DNA (IP)

DNA Sequencing (IP)

Analyze for low frequency mutant alleles

Report Screening Results